Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC).

被引：0
|
作者：
Ikeda, Masafumi
Aramaki, Takeshi
Inaba, Yoshitaka
Nakai, Kenya
Doi, Toshihiko
Okusaka, Takuji
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Aichi Canc Ctr Hosp, Dept Intervent & Diagnost Radiol, Nagoya, Aichi 464, Japan
[4] Eisai & Co Ltd, Tokyo, Japan
[5] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
    Toshihiko Doi
    Takeshi Aramaki
    Hirofumi Yasui
    Kei Muro
    Masafumi Ikeda
    Takuji Okusaka
    Yoshitaka Inaba
    Kenya Nakai
    Hiroki Ikezawa
    Ryo Nakajima
    Investigational New Drugs, 2019, 37 : 1061 - 1074
  • [2] A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
    Doi, Toshihiko
    Aramaki, Takeshi
    Yasui, Hirofumi
    Muro, Kei
    Ikeda, Masafumi
    Okusaka, Takuji
    Inaba, Yoshitaka
    Nakai, Kenya
    Ikezawa, Hiroki
    Nakajima, Ryo
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (05) : 1061 - 1074
  • [3] A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
    D'Angelo, Sandra P.
    Hamid, Omid A.
    Tarhini, Ahmad
    Schadendorf, Dirk
    Chmielowski, Bartosz
    Collichio, Frances A.
    Pavlick, Anna C.
    Lewis, Karl D.
    Weil, Susan C.
    Heyburn, John
    Schweizer, Charles
    O'Shannessy, Daniel J.
    Carvajal, Richard D.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 103 - 113
  • [4] A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
    Sandra P. D’Angelo
    Omid A. Hamid
    Ahmad Tarhini
    Dirk Schadendorf
    Bartosz Chmielowski
    Frances A. Collichio
    Anna C. Pavlick
    Karl D. Lewis
    Susan C. Weil
    John Heyburn
    Charles Schweizer
    Daniel J. O’Shannessy
    Richard D. Carvajal
    Investigational New Drugs, 2018, 36 : 103 - 113
  • [5] A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC)
    Okusaka, Takuji
    Ikeda, Masafumi
    Ohkawa, Shinichi
    Yamamoto, Shunsuke
    Suzuki, Ikue
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors
    Diaz, Luis A.
    Azad, Nilofer Saba
    Gounder, Mrinal M.
    Coughlin, Christina Marie
    Fishel, Jean
    O'Shannessy, Daniel
    Grasso, Luigi
    Wustner, Jason
    Aluri, Jagadeesh
    Parno, Jeff
    Carvajal, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
    Zhu, A. X.
    Gold, P. J.
    El-Khoueiry, A. B.
    Abrams, T. A.
    Morikawa, H.
    Ohtomo, T.
    Philip, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors.
    Carvajal, R. D.
    Gounder, M. M.
    Coughlin, C. M.
    Fishel, J.
    Heyburn, J.
    O'Shannessy, D.
    Grasso, L.
    Schweizer, C.
    Parno, J.
    Old, L. J.
    Azad, N. S.
    Diaz, L. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Furuse, J.
    Ishii, H.
    Nakajima, K.
    Nakachi, K.
    Suzuki, E.
    Yoshino, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 114 - 114
  • [10] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Furuse, Junji
    Ishii, Hiroshi
    Nakachi, Kohei
    Suzuki, Eiichiro
    Shimizu, Satoshi
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (01) : 159 - 165
12345